Enfermedad pulmonar intersticial asociada a esclerosis sistémica (EPI-ES)
Effects of nintedanib on circulating biomarkers in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Assassi S et al.
“Effective lung age” in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the SENSCIS trial
Maher TM et al.
Baseline characteristics of patients with improvement or progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD) during the SENSCIS trial
Hoffmann-Vold AM et al.
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) and risk factors for rapid decline in forced vital capacity: further analyses of the SENSCIS trial
Khanna D et al.
Continued treatment with nintedanib in patients with limited cutaneous systemic sclerosis (lcSSc) and interstitial lung disease (ILD)
Allanore Y et al.
SC-ES-09814